Notably, the MCD subtype accounted for more than half of the CD5+ DLBCL cases, which was significantly higher than that observed for CD5- DLBCL (54.17% vs. 13.04%, P = 0.005). This evidence concerns the gene CD5 and diffuse large B-cell lymphoma.